Myocardial infarction · patients with acute coronary syndrome
It is very uncertain whether drug‐eluting stents changes myocardial infarction at maximum compared with bare‐metal stents (very low certainty).
1 finding from 1 review
Angina · patients with acute coronary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower all‐cause mortality compared with bare stents (low certainty).
1 finding from 1 review
Hepatic encephalopathy · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes hepatic encephalopathy compared with bare stents (very low certainty).
2 findings from 1 review
Kidney failure · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes kidney failure compared with bare stents (very low certainty).
1 finding from 1 review
Shunt dysfunctiona · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower shunt dysfunctiona compared with bare stents (low certainty).
1 finding from 1 review
Upper gastrointestinal bleeding · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower upper gastrointestinal bleeding compared with bare stents (low certainty).
2 findings from 1 review
Recurrence of ascites · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower recurrence of ascites compared with bare stents (low certainty).
2 findings from 1 review
Shunt dysfunction · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower shunt dysfunction compared with bare stents (low certainty).
1 finding from 1 review
Total mortalitya · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes all‐cause mortalitya compared with bare stents (very low certainty).
1 finding from 1 review
Procedure‐related complications · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes procedure‐related complications compared with bare stents (very low certainty).
1 finding from 1 review
Units SGRQ at end of · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change from baseline in lung function parameters other than FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Six‐minute walk distance · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events at end of · patients with chronic obstructive pulmonary disease
Airway bypass stents showed no clear difference in adverse events at end of compared with control (moderate certainty).
1 finding from 1 review
Cost‐effectiveness · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: relative change from baseline · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Mortality at end of · patients with chronic obstructive pulmonary disease
Airway bypass stents showed no clear difference in mortality at end of compared with control (moderate certainty).
1 finding from 1 review